ArticleJournal of nanobiotechnology2026
A stimuli-responsive mitochondria-targeted nanoplatform for glioblastoma therapy: modulating the blood-brain barrier and delivering precise chemotherapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The blood brain barrier (BBB) is crucial for maintaining homeostasis within the central nervous system (CNS). Its impairment under pathological conditions significantly compromises the efficacy of chemotherapy for glioblastoma (GBM). Therefore, strategies to promote BBB functional recovery could provide a valuable adjunct to GBM chemotherapy. Mitochondria, the primary cellular "powerhouses", are key organelles regulating apoptosis. Mitochondrial dysfunction in either BBB or GBM cells is closely associated with barrier disruption and enhanced tumor cell apoptosis, respectively. This positions mitochondria as a promising dual target for modulating BBB integrity and enabling targeted chemotherapy. Celastrol (Cela), a natural pentacyclic triterpenoid isolated from the traditional Chinese medicine (TCM) Tripterygium wilfordii, has been shown to exhibit many pharmacological activities, including anti-tumor, anti-fibrosis, anti-inflammatory, immunomodulation, antioxidant, and neuroprotective effects. In addition, Cela has been widely used as a mitochondrial protector in CNS disorders, and it also safeguards endothelial cells from apoptosis, which helps maintain the structural and functional integrity of the BBB. However, the applications of Cels are still limited due to its poor water stability, non-specific distribution, low bioavailability, and high systemic toxicity. In this study, we developed a stimuli-responsive mitochondria-targeted nanoplatform encapsulating Cela, termed Cela@Lip-IRH, for the precise treatment of GBM. The incorporation of IR780 facilitated cellular uptake and promoted mitochondrial co-localization of Cela@Lip-IRH in both BBB and GBM cells in vitro. Furthermore, the nanoplatform exhibited enhanced BBB penetration and achieved specific accumulation in GBM tumors in vivo. We systematically investigated the anti-tumor efficacy and underlying mechanisms of Cela@Lip-IRH, focusing on mitochondrial function-dependent BBB restoration and the induction of tumor cell apoptosis. Collectively, this work provided novel therapeutic strategies and mechanistic insights for targeted GBM therapy, positioning Cela@Lip-IRH as a promising nanoplatform for modulating mitochondrial activity. Moreover, the combined strategy of BBB repair and chemotherapy may have broader implications for treating a range of neurological disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.